The Galician biotechnology company Qubiotech Health Intelligencededicated to the development and commercialization of software to improve the diagnosis and follow-up of neurodegenerative diseases through image processing based on Artificial Intelligence and a partner of the Cluster Tecnolóxico Empresarial das Ciencias da Vida (Bioga), has closed a round of financing giving entry into its shareholders to the specialized funds “Sémola Tech Ventures” and “Nowture”.
“The entry of “Nowture” and “Semola Tech Ventures” into our shareholding is very positive for the company due to the synergies and knowledge that they contribute at a time of growth in the Artificial Intelligence sector”, says Daniel Fernández Mosquera, General Director of Qubiotech. Qubiotech’s current partners have highly valued that Sémola Tech Ventures knows first-hand, through its managers Santi Domínguez and Carlos Cobas, how to grow and internationalize a scientific software company, so their experience is directly applicable to Qubiotech. Nowture, for its part, provides extensive knowledge and experience in acceleration, value generation and internationalization of biotechnology companies in their early stages of development. Both funds not only provide capital and networking, but will actively participate in the company’s decision-making.
SEMOLA Tech Ventures is an investment company created by the founding partners of the company Mestrelab Research Javier Sardina López, Carlos Cobas Gómez and Santiago Domínguez. Its mission is to finance projects (seed phase) focused on life sciences and biotechnology and serve as traction for other investors to join projects in more advanced phases. To do this, they provide not only economic financing, but also both the technical know-how that they need in said seed phase and the experience in business development and market access through a minimum viable product.
“Qubiotech is a project that fits perfectly with Semola’s investment philosophy. The company has a high content of specialized knowledge and a technological edge that gives it potential leadership in the global market it focuses on. It has already demonstrated its ability to offer quality products to the end customer and is ready for a phase of internationalization and professionalization of the market access phase that offers a great opportunity for growth, to which we believe that we can contribute significantly, not only with capital, but also with our experience in this phase of the growth of a business”, affirms Carlos Cobas, co-founder of Sémola Tech Ventures SL.
Nowture is a Venture Builder oriented to the creation, development and acceleration of innovative startups with high growth potential in Biotechnology and Life Sciences. Qubiotech has its target market -especially- in neurodegenerative diseases, which is one of the areas of specialization of the Nowture scientific and technical team. With this new investment, Nowture not only increases its investee portfolio, but also enhances its growth through the synergies already identified and that, without a doubt, will accelerate its growth.
Nowture’s experience in emerging markets, as well as in the internationalization of biotechnology companies, will allow Qubiotech to reach commercialization agreements in new markets with high growth potential.
Qubiotech markets the “Neurocloud” neuroimaging analysis platform. This platform is one of the few products on the market that houses tools that allow analysis of brain images acquired with Positron Emission Tomography (PET), Magnetic Resonance Imaging (MR) and Single Photon Emission Computed Tomography (SPECT), facilitating the detection and quantification of abnormalities in the same environment for physicians of Nuclear Medicine, Radiology and Neurology. Today Neurocloud is used in 20 hospitals in Spain and Portugal and has already helped interpret more than 7,000 images of patients with diseases such as dementia, Alzheimer’s, Parkinson’s, multiple sclerosis or epilepsy.
Qubiotech’s R&D strategy in the 2023-2025 period focuses on the development of Artificial Intelligence algorithms focused on oncological image analysis using PET and MR. The first of them, aimed at facilitating the diagnosis and monitoring of glioblastoma, has obtained funding for two R&D projects from the Ministry of Science in its calls for Strategic Lines 2021 and 2022.
